PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Sloan Kettering Institute For Cancer Research

USPTO PatentsView assignee record — 93 granted patents across 23 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
93
Total patents granted
23
CPC technology areas
18.3
Avg claims per patent
-52%
5-year filing velocity

The verdict

Sloan holds 93 US patents across 23 technology areas — rank #3,898 of 50,000 tracked assignees.

#3,898
of 50,000 US assignees by volume
Top 21%
by Innovation Score (46.4/100)
18.3
avg claims per patent
-52%
filing velocity, last 5 yrs

Portfolio overview

Sloan Kettering Institute for Cancer Research has been granted 93 US utility patents between 2015 and 2025, placing Sloan Kettering Institute for Cancer Research at rank #3,898 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Sloan Kettering Institute for Cancer Research is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 46.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 30 grants, compared with 63 in the 2015–2019 window — a -52% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sloan Kettering Institute for Cancer Research's 18.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sloan Kettering Institute for Cancer Research against peers pursuing similar technology classes.

How does Sloan compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Sloan holds 93 patents — placing it at rank #3,898 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Sloan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

46 Top 21% higher than 79% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

05101520 20152016201720182019202020212022202320242025 4
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Sloan Kettering Institute for Cancer Research patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 12 12.9%
2016 19 20.4%
2017 12 12.9%
2018 12 12.9%
2019 8 8.6%
2020 11 11.8%
2021 5 5.4%
2022 2 2.2%
2023 4 4.3%
2024 4 4.3%
2025 4 4.3%

Which technologies does Sloan Kettering Institute for Cancer Research patent most?

Top 15 of 23 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#3,898

Across all tracked assignees

Innovation Score

46.4 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Sloan Kettering Institute for Cancer Research hold?
Sloan Kettering Institute for Cancer Research holds 93 US granted patents filed between 2015 and 2025, spanning 23 technology areas.
What is Sloan Kettering Institute for Cancer Research's Innovation Score?
Sloan Kettering Institute for Cancer Research has an Innovation Score of 46.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Sloan Kettering Institute for Cancer Research focus on?
Sloan Kettering Institute for Cancer Research's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 69 patents. The company has filed patents in 23 CPC subclasses total.
Is Sloan Kettering Institute for Cancer Research's patent filing rate increasing or decreasing?
Sloan Kettering Institute for Cancer Research's recent filing velocity is -52% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Sloan Kettering Institute for Cancer Research's patents?
Sloan Kettering Institute for Cancer Research's patents average 18.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Sloan Kettering Institute for Cancer Research patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Sloan's 93 grants land it in the top 21% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Sloan ranks #3,898 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P — see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

A61P technology

Sloan Kettering Institute for Cancer Research's primary CPC class — all holders and yearly trends
Top 50 patent holders

See where Sloan Kettering Institute for Cancer Research ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov